Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits
Radiotherapy Shows Potential Cost Savings for Macular Degeneration Patients
Researchers evaluated the impact of stereotactic radiotherapy alongside ranibizumab for patients with neovascular age-related macular degene…
A trial suggests that adding stereotactic radiotherapy to standard care may lower healthcare costs and help track quality of life in macular…
Gene therapy significantly reduces central subfield thickness in neovascular age-related macular degeneration
Gene Therapy Shows Potential to Reduce Swelling in Macular Degeneration
This meta-analysis of early-phase trials evaluates gene therapy for neovascular age-related macular degeneration. While a significant anatom…
New gene therapy research shows significant reduction in retinal swelling for patients with neovascular age-related macular degeneration.
Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity
Higher doses of aflibercept show similar results for macular degeneration
This post hoc descriptive subgroup analysis of a randomized controlled trial involving 869 treatment-naže patients with neovascular age-rela…
A higher dose of aflibercept may offer the same vision benefits as lower doses for patients with neovascular age-related macular degeneratio…
One-off 16 Gray stereotactic radiotherapy reduces anti-VEGF injections but results in worse visual acuity
Radiation for wet AMD cuts injections but harms vision
This randomized controlled trial of 411 patients with neovascular age-related macular degeneration found that one-off 16 Gray stereotactic r…
A single dose of radiation reduced the number of eye injections needed for wet AMD, but patients ended up with worse vision after four years…
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
AI fluid measurements better predict vision loss than thickness in AMD
This randomized phase III trial in 290 eyes with neovascular AMD found that AI-based quantification of intraretinal and subretinal fluid vol…
AI-based fluid volume tracking explains more vision changes than standard thickness measurements in macular degeneration patients.
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
Research across Age-Related Macular Degeneration
Related studies from across the Age-Related Macular Degeneration family.
Photobiomodulation protocol aims to consolidate preclinical evidence for ophthalmic diseases
Planning to Review Light Therapy for Common Eye Diseases and Injuries
This is a protocol for a systematic review and meta-analysis, not a completed study. It outlines plans to evaluate photobiomodulation (PBM) …
Experts are planning a large review to see if light therapy can help treat common eye problems like glaucoma and vision loss.
Marine compounds from Mexican Pacific Sargassum may protect against AMD progression in preclinical models
Marine compounds from seaweed may protect eyes from age-related degeneration
This narrative review examines marine-derived bioactive compounds from Mexican Pacific Sargassum, including fucoxanthin, fucoidans, phlorota…
Scientists are exploring how specific compounds found in Mexican Pacific seaweed could slow the progression of age-related macular degenerat…
Central 2.50-mm geographic atrophy extent correlates with visual function measures in age-related macular degeneration
Central vision loss impacts daily life for geographic atrophy patients
This observational analysis of Phase III clinical trial data involved 856 individuals aged 50 years or more with bilateral geographic atroph…
New analysis shows that damage in the very center of the eye most affects how people with geographic atrophy experience their daily lives.
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity
Faricimab shows better vision outcomes for age related macular degeneration
This meta-analysis of 8 studies involving 8458 study populations found that faricimab 6 mg every sixteen weeks showed superior effects on be…
A new treatment option for age related macular degeneration may offer better vision and thinner retinal tissue than current standard drugs.
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion
Eye Drug Comparison Shows Similar Vision Gains
This meta-analysis of 759 patients with RVO-ME found no significant difference between intravitreal ranibizumab and bevacizumab monotherapy …
Two common eye injections work equally well for swelling caused by retinal vein blockage, a new analysis finds.
CFH Y402H and ARMS2 A69S polymorphisms are associated with increased risk of age-related macular degeneration
Specific genes linked to higher risk of age related macular degeneration
This meta-analysis evaluates the association between specific genetic polymorphisms and age-related macular degeneration (AMD) risk. The ana…
New research identifies two specific genetic variations that significantly increase the risk of developing age-related macular degeneration.
Anti-VEGF plus corticosteroids improves BCVA and reduces edema recurrence in BRVO and CRVO
Combination therapy improves vision for patients with retinal vein occlusion
This meta-analysis of 2040 patients found that anti-VEGF plus corticosteroid combination therapy resulted in better BCVA (MD -0.09) and redu…
Adding corticosteroids to anti-VEGF injections can improve vision and reduce the need for frequent eye injections in certain retinal conditi…
Migraine patients may have an increased risk of neovascular age-related macular degeneration
Migraine patients may face higher risk of certain eye conditions
This narrative review examines the association between migraine and various retinal conditions, including retinal migraine and AMD. The auth…
New research highlights a link between migraines and age-related macular degeneration, potentially impacting long-term vision for many suffe…
Age, smoking, and systemic factors are associated with increased risk of age-related macular degeneration
Risk Factors Linked to Age-Related Macular Degeneration
This umbrella review synthesizes epidemiological evidence regarding 53 distinct risk factors for age-related macular degeneration. The analy…
New research identifies how lifestyle factors like smoking, diet, and high blood pressure may link to age-related macular degeneration.
Deep learning algorithms outperform ophthalmologists in detecting AMD and differentiating wet from dry cases
Deep learning algorithms outperform doctors in detecting age-related macular degeneration
This systematic review and meta-analysis evaluates the diagnostic performance of deep learning (DL) algorithms for identifying age-related m…
New data shows deep learning tools can identify eye diseases with higher accuracy than senior specialists, offering a powerful new way to sc…
Obstructive Sleep Apnea Associated with Higher Odds of Age-Related Macular Degeneration
Large study links obstructive sleep apnea to higher risk of age-related macular degeneration
A systematic review and meta-analysis of 3,536,314 adults found that obstructive sleep apnea (OSA) was associated with higher odds of age-re…
A massive analysis of over 3.5 million people suggests obstructive sleep apnea is linked to a higher risk of age-related macular degeneratio…
Systematic review and meta-analysis finds no significant association between diabetic retinopathy and age-related macular degeneration
Diabetic retinopathy and age-related macular degeneration show no significant link
This systematic review and meta-analysis evaluates the association between diabetic retinopathy and age-related macular degeneration.
A meta-analysis found no significant relationship between diabetic retinopathy and age-related macular degeneration, though existing data ha…
Questions about Neovascular Age-Related Macular Degeneration
What happens to my immune system when I get anti-VEGF injections for AMD?
Anti-VEGF injections for AMD block abnormal blood vessel growth but may also activate immune pathways, including T-cell and inflammatory signals, which could affect long-term outcomes.
Full answer →Can the FDA-approved drug Eylea HD be used to treat my neovascular AMD?
Yes, Eylea HD (aflibercept) is FDA-approved to treat neovascular (wet) age-related macular degeneration (nAMD).
Full answer →Does combining radiotherapy with anti-VEGF therapy increase my risk of losing vision?
Yes, combining radiotherapy with anti-VEGF therapy increases the risk of vision loss compared to anti-VEGF alone, based on systematic reviews.
Full answer →Are aflibercept biosimilars just as safe and effective as the original drug for AMD?
Yes, aflibercept biosimilars are as safe and effective as the original drug for neovascular AMD, based on a meta-analysis of 11 studies.
Full answer →Does the FDA approval of Pavblu mean it can treat my neovascular AMD?
Yes, Pavblu (aflibercept) is FDA-approved specifically for neovascular AMD, so it can treat your condition.
Full answer →All Neovascular Age-Related Macular Degeneration Articles
- Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits
- Gene therapy significantly reduces central subfield thickness in neovascular age-related macular degeneration
- Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity
- One-off 16 Gray stereotactic radiotherapy reduces anti-VEGF injections but results in worse visual acuity
- FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
- AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
- Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
- Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
- Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
- FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
- Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
- FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
- Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD